Compare DKS & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DKS | EXAS |
|---|---|---|
| Founded | 1948 | 1995 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6B | 19.6B |
| IPO Year | 2002 | 2000 |
| Metric | DKS | EXAS |
|---|---|---|
| Price | $202.72 | $103.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 19 |
| Target Price | ★ $241.50 | $84.27 |
| AVG Volume (30 Days) | 923.4K | ★ 2.2M |
| Earning Date | 02-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | 15.35 | ★ 80.32 |
| EPS | ★ 8.66 | N/A |
| Revenue | ★ $13,442,849,000.00 | $4,144,000.00 |
| Revenue This Year | $30.99 | $15.18 |
| Revenue Next Year | $26.26 | $12.46 |
| P/E Ratio | $23.56 | ★ N/A |
| Revenue Growth | ★ 3.53 | N/A |
| 52 Week Low | $166.37 | $38.88 |
| 52 Week High | $237.31 | $103.87 |
| Indicator | DKS | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 67.66 |
| Support Level | $198.00 | $103.14 |
| Resistance Level | $207.31 | $103.42 |
| Average True Range (ATR) | 6.43 | 0.34 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 28.55 | 67.53 |
Dick's Sporting Goods is a retailer that offers sports and outdoor apparel, footwear, and equipment online and in physical stores. The company's legacy business includes more than 700 stores under its own name, more than 110 Golf Galaxy golf specialty stores, and about 50 outlet stores. In September 2025, Dick's acquired multinational retailer Foot Locker. With this move, Dick's added about 2,600 stores under the Foot Locker, Kids Foot Locker, Champs Sports, atmos, and WSS nameplates in North America, the Asia-Pacific, and EMEA—Europe, the Middle East, and Africa. Based in the Pittsburgh area, Dick's was founded in 1948 by the father of current executive chair and controlling shareholder Edward Stack.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.